

ATTORNEY DOCKET NO.: 12987.54

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Guy Boileau et al. Examiner: Not yet assigned  
Serial No.: Not yet assigned Art Unit: Unknown  
Filing Date: Concurrently filed  
Title: PHEX SUBSTRATES AND METHODS USING SAME

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION**  
**(37 CFR § 3.73(b))**

The inventors of the above-referenced United States patent application have assigned their entire right, title, and interest in the inventions disclosed therein according to the following table:

Inventor	Assignee
Guy Boileau	<i>Enobia Pharma Inc.</i>
Adriana Karaoglanovic Carmona	<i>Enobia Pharma Inc.</i>
Marcelo Campos	<i>Enobia Pharma Inc.</i>
Maria Aparecida Juliano	<i>Enobia Pharma Inc.</i>
Luiz Juliano	<i>Enobia Pharma Inc.</i>

Thus, the Assignee of the inventors' entire right, title, and interest is:

Enobia Pharma Inc.

According to 37 CFR § 3.73(b), the Assignee is entitled to take action relating to the application in the Patent and Trademark Office if the Assignee establishes ownership to the satisfaction of the Commissioner.

Ownership by the assignee is established as follows:

\_\_\_\_\_ documents already recorded in the PTO on \_\_\_\_\_.

Reel \_\_\_\_\_ Frame \_\_\_\_\_; and

☒ documents separately submitted for recordal to the PTO (a copy of these documents is attached).

### STATEMENT

I, person(s) authorized to sign on behalf of the Assignee, have reviewed the evidentiary documents referred to above and certify that, to the best of my knowledge and belief, title is mine/ours as Assignee who seeks to take further action.

Name/Title	Assignee	Date
Signature: <u>P. Crine</u> Name: <u>P. CRINE</u> Title: <u>CSO.</u>	Enobia Pharma Inc.	Jan 6, 2006.
Signature: _____ Name: _____ Title: _____		

**ASSIGNMENT OF INVENTION****UNIVERSAL**

WHEREAS, We, 1) BOILEAU, Guy; 2) CARMONA, Adriana, Karaoglanovic; 3) CAMPOS, Marcelo; 4) JULIANO, Maria, Aparecida; 5) JULIANO, Luiz, whose full addresses are 1) 7645 Malherbe, Brossard, Quebec, Canada, H3C 3J7; 2) Alameda Sarutaia 103, Apto 161, CEP-01403-010 Sao Paulo, SP, Brazil; 3) Rua Rocha 46A, Apto 205, CEP-01330-000, Sao Paulo, SP, Brazil; 4) Rua Frei Gaspar 568, CEP-03048-020 Sao Paulo, SP, Brazil; 5) Rua Rouxinol 795, Apto 94, CEP-04516-001 Sao Paulo, SP, Brazil (hereinafter referred to as the assignors); have invented PHEX SUBSTRATES AND METHODS USING SAME described in International Patent Application No. PCT/CA2004/000453 filed on March 25, 2004, claiming priority of US patent application No. 60/457,296 filed on March 26, 2003;

and:

WHEREAS ENOBIA PHARMA INC. , whose full post office address is 2901 rue Rachel Est, suite 23, Montreal, Quebec, Canada, H1W 4A4 (hereinafter referred to as the assignee), is desirous of acquiring the entire right, title and interest in and to said invention or inventions and in and to any and all patents to be obtained therefor;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other valuable consideration, the receipt of which is hereby acknowledged, We have and by these present do hereby sell, assign and transfer unto said assignee, its successors and assigns, the entire right, title and interest in and to said invention or inventions, as described in the aforesaid application, in any form or embodiment thereof, and in and to the aforesaid application; and in and to any applications based thereon filed in any foreign country, including the right to file said foreign applications under the provisions of the Patent Cooperation Treaty and under the Paris Convention; also the entire right, title and interest in and to any and all patents, reissues or extensions thereof to be obtained in this or any

foreign country upon said invention or inventions, and any divisional, continuation, continuation-in-part, substitute application(s) or supplementary disclosure(s) which may be filed upon said invention or inventions, in any country; and We hereby authorize and request the issuing authority to issue any and all patents on said application or applications to said assignee.

We further agree without any payment by said assignee other than expenses incurred by the undersigned, to communicate to said assignee, its representatives or agents, any facts useful as evidence for interference purposes or for other proceedings relating to intellectual property encompassing the invention, whenever requested; testify in any interference, litigation or other proceedings, whenever requested; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective, and likewise make these provisions binding upon our heirs, legal representatives, administrators and assigns.

Les soussignés désirent que la présente cession soit en anglais. The undersigned request that the present assignment be in English.

IN WITNESS WHEREOF, We have hereunto set our hands and seal.


WITNESS(ES)

DATE

ASSIGNOR(S)

  
Signature of Witness


10/23/2005  
MM/DD/YYYY

  
Guy Bolleau

P. C. RINE  
Name of Witness

  
Signature of Witness

10/26/2005  
MM/DD/YYYY

  
Adriana Karaoglanovic Carmona

P. C. RINE  
Name of Witness

P. Crine  
Signature of Witness

10/25/2005  
MM/DD/YYYY

Marcelo Campos  
Signature of assigned representative of Enobia Pharma Inc.

P. CRINE  
Name of Witness

P. Crine  
Signature of Witness

10/26/2005  
MM/DD/YYYY

Maria Aparecida Juliano  
Signature of assigned representative of Enobia Pharma Inc.

P. CRINE  
Name of Witness

P. Crine  
Signature of Witness

10/26/2005  
MM/DD/YYYY

Luiz Julliano  
Signature of assigned representative of Enobia Pharma Inc.

P. CRINE  
Name of Witness

WITNESS(ES)

DATE

ASSIGNEE(S)

P. Crine  
Signature of Witness

11/17/2005  
MM/DD/YYYY

Luc Courdoyer  
Signature of authorized representative of Enobia Pharma Inc.

PHILIPPE CRINE  
Name of Witness

Luc Courdoyer  
Name of authorized representative of Enobia Pharma Inc.

VP FINANCE  
Title of authorized representative of Enobia Pharma Inc.

The Assignment is executed nunc pro tunc as of March 26, 2003